\-\ Texto\\:\\ \ \(0\)\
\-\ non\\-contributory\ \(73\)\
\-\ follow\\-up\\ mri\\ three\\ weeks\\ later\\ revealed\\ subtotal\\ resolution\\ of\\ many\\ of\\ the\\ lesions\\.\\ this\\ is\\ consistent\\ with\\ the\\ monophasic\\ illness\\ of\\ most\\ patients\\ with\\ adem\\.\ \(0\)\
\-\ multiple\\ enhancing\\ brain\\ lesions\\ with\\ increased\\ t2\\ signal\\ intensity\\.\\ lesions\\ involve\\ cerebral\\ white\\ matter\\,\\ gray\\ matter\\,\\ and\\ cerebellum\\.\\ no\\ mass\\ effect\\.\\ no\\ restricted\\ diffusion\\.\\ minimal\\ enhancement\\.\ \(0\)\
\-\ acute\\ disseminated\\ encephalomyelitis\ \(7\)\
\-\ \\â\\€\\¢\\ multiple\\ sclerosis\ \(0\)\
\-\ \\â\\€\\¢\\ multiple\\ infarcts\ \(0\)\
\-\ \\â\\€\\¢\\ sickle\\ cell\\ disease\ \(0\)\
\-\ \\â\\€\\¢\\ adem\\ \\(acute\\ disseminated\\ encephalo\\-myelitis\\)\ \(0\)\
\-\ 4\\ y\\.o\\.\\ girl\\ presents\\ with\\ lethargy\\ and\\ possible\\ seizure\\.\ \(1\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ disseminated\\:\\ 0\\.30854184580758076\ \(0\)\
\-\ adem\\:\\ 0\\.3059801881366181\ \(0\)\
\-\ lesions\\:\\ 0\\.24541797684707797\ \(0\)\
\-\ matter\\:\\ 0\\.2169151777399408\ \(0\)\
\-\ multiple\\:\\ 0\\.209014283058101\ \(0\)\
\-\ monophasic\\:\\ 0\\.19651323626328138\ \(0\)\
\-\ subtotal\\:\\ 0\\.17920487448433428\ \(0\)\
\-\ encephalomyelitis\\:\\ 0\\.16680850403124586\ \(0\)\
\-\ lethargy\\:\\ 0\\.15856214200142674\ \(0\)\
\-\ acute\\:\\ 0\\.15411123145284375\ \(0\)\
\-\ illness\\:\\ 0\\.14328503678139892\ \(0\)\
\-\ sickle\\:\\ 0\\.14086663002237929\ \(0\)\
\-\ infarcts\\:\\ 0\\.13937539966269938\ \(0\)\
\-\ cerebellum\\:\\ 0\\.13087027171406843\ \(0\)\
\-\ involve\\:\\ 0\\.12534976288635644\ \(0\)\
\-\ restricted\\:\\ 0\\.12243157994495704\ \(0\)\
\-\ gray\\:\\ 0\\.121886743326458\ \(0\)\
\-\ diffusion\\:\\ 0\\.1199849417666449\ \(0\)\
\-\ seizure\\:\\ 0\\.11852992705900477\ \(0\)\
\-\ resolution\\:\\ 0\\.11557135993628029\ \(0\)\
\-\ many\\:\\ 0\\.11230683735535767\ \(0\)\
\-\ with\\:\\ 0\\.11156761008163851\ \(0\)\
\-\ minimal\\:\\ 0\\.10866831322350472\ \(0\)\
\-\ later\\:\\ 0\\.10193847636800811\ \(0\)\
\-\ sclerosis\\:\\ 0\\.10145825603517654\ \(0\)\
\-\ intensity\\:\\ 0\\.10114316431234188\ \(0\)\
\-\ effect\\:\\ 0\\.09992111311334688\ \(0\)\
\-\ girl\\:\\ 0\\.09992111311334688\ \(0\)\
\-\ cerebral\\:\\ 0\\.09868504799652383\ \(0\)\
\-\ possible\\:\\ 0\\.09651231407498606\ \(0\)\
\-\ three\\:\\ 0\\.09561812741483104\ \(0\)\
\-\ white\\:\\ 0\\.09397912229977459\ \(0\)\
\-\ revealed\\:\\ 0\\.0933983824576864\ \(0\)\
\-\ no\\:\\ 0\\.09264096255027741\ \(0\)\
\-\ enhancing\\:\\ 0\\.0892313431533472\ \(0\)\
\-\ brain\\:\\ 0\\.08879789699675202\ \(0\)\
\-\ weeks\\:\\ 0\\.0853682182087507\ \(0\)\
\-\ of\\:\\ 0\\.08362574120078833\ \(0\)\
\-\ enhancement\\:\\ 0\\.0819870713043413\ \(0\)\
\-\ t2\\:\\ 0\\.08195075029764029\ \(0\)\
\-\ cell\\:\\ 0\\.08148332276840975\ \(0\)\
\-\ signal\\:\\ 0\\.08074625669036564\ \(0\)\
\-\ patients\\:\\ 0\\.08013135232439672\ \(0\)\
\-\ consistent\\:\\ 0\\.07723526173653854\ \(0\)\
\-\ increased\\:\\ 0\\.07702579997636678\ \(0\)\
\-\ most\\:\\ 0\\.07413107202779812\ \(0\)\
\-\ mri\\:\\ 0\\.07311702658149445\ \(0\)\
\-\ presents\\:\\ 0\\.06852190083968945\ \(0\)\
\-\ disease\\:\\ 0\\.05979204443070265\ \(0\)\
\-\ and\\:\\ 0\\.058867744624440985\ \(0\)\
\-\ the\\:\\ 0\\.05684463611015206\ \(0\)\
\-\ mass\\:\\ 0\\.05440899882061858\ \(0\)\
\-\ this\\:\\ 0\\.04894559799597613\ \(0\)\
\-\ is\\:\\ 0\\.03900867886834033\ \(0\)\
